Skip to content Skip to footer

Murj Expands Commercial Operations Across Australia and New Zealand for Cardiac Device Management Solutions

Shots: Murj announced the commercial launch of its cardiac device management platform in Australia and expanded availability in New Zealand, following its participation at the CSANZ/HRS Advances in Pacing and Conduction System Pacing Summit in Melbourne The expansion enables healthcare providers across the region to access Murj’s cloud-native solutions for cardiac implantable electronic device (CIED)…

Read more

Kashiv Biosciences submits a BLA to the US FDA and receives EMA MAA acceptance for ADL-018 (Biosimilar, Xolair) 

Shots:  Kashiv BioSciences submitted a BLA to the US FDA and received EMA MAA acceptance for ADL-018, a proposed biosimilar to Xolair (omalizumab)  ADL-018 is a humanized mAb biosimilar to Xolair (omalizumab), designed to block IgE binding on mast cells and basophils. Xolair is approved for CSU (≥12 yrs), moderate-to-severe asthma (≥6 yrs), chronic rhinosinusitis…

Read more